Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-7000 in Refractory Focal Onset Epilepsy
NCT06309966Phase 3Active, not recruiting
- Sponsor
- Biohaven Ltd.
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of opakalim in Focal Onset Epilepsy, sponsored by Biohaven Ltd.. Started May 2024; status: active, not recruiting.
02
Drugs
opakalim
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on NCT06309966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06309966.